Search Results - Langmuir, Peter

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    JAK inhibitors and COVID-19

    JAK inhibitors and COVID-19 by Levy, Gabriel, Guglielmelli, Paola, Langmuir, Peter, Constantinescu, Stefan N

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm

    Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm by Langmuir, Peter, Yeleswaram, Swamy, Smith, Paul, Knorr, Barbara, Squier, Peg

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

    Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment by Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance

    Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance by Kishimoto, Koji, Sandner, Sigrid, Imitola, Jaime, Sho, Masayuki, Li, Yongsheng, Langmuir, Peter B., Rothstein, David M., Strom, Terry B., Turka, Laurence A., Sayegh, Mohamed H.

    Published 2002
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

    Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer by Hanrahan, Emer O., Lin, Heather Y., Kim, Edward S., Yan, Shaoyu, Du, Danny Z., McKee, Kathryn S., Tran, Hai T., Lee, J. Jack, Ryan, Anderson J., Langmuir, Peter, Johnson, Bruce E., Heymach, John V.

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

    Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses by Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

    Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial by Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

    Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial by Herbst, Roy S, Sun, Yan, Eberhardt, Wilfried E E, Germonpré, Paul, Saijo, Nagahiro, Zhou, Caicun, Wang, Jie, Li, Longyun, Kabbinavar, Fairooz, Ichinose, Yukito, Qin, Shukui, Zhang, Li, Biesma, Bonne, Heymach, John V, Langmuir, Peter, Kennedy, Sarah J, Tada, Hiroomi, Johnson, Bruce E

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

    A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease by Schroeder, Mark A., Khoury, H. Jean, Jagasia, Madan, Ali, Haris, Schiller, Gary J., Staser, Karl, Choi, Jaebok, Gehrs, Leah, Arbushites, Michael C., Yan, Ying, Langmuir, Peter, Srinivas, Nithya, Pratta, Michael, Perales, Miguel-Angel, Chen, Yi-Bin, Meyers, Gabrielle, DiPersio, John F.

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

    Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 tri... by Han, MeiLan K, Antila, Martti, Ficker, Joachim H, Gordeev, Ivan, Guerreros, Alfredo, Bernus, Amparo Lopez, Roquilly, Antoine, Sifuentes-Osornio, José, Tabak, Fehmi, Teijeiro, Ricardo, Bandelli, Lorraine, Bonagura, Diane S, Shu, Xu, Felser, James M, Knorr, Barbara, Cao, Weihua, Langmuir, Peter, Lehmann, Thomas, Levine, Michael, Savic, Sinisa

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: